[Effect of the angiotensin II analog saralasin before donor nephrectomy on primary transplant function].
Cadaver kidney donors were treated with Angiotensin II-Analogon-Saralasin before nephrectomy in order to reduce the rate of acute renal failure. Eighteen (64.3%) of the recipients of the 30 donor kidneys pretreated with Saralasin were primarily free from dialysis. Six recipients showed acute renal failure. Two donor kidneys never resumed their function and no reports could be obtained on two organs. In the control-group with no pre-treatment, acute renal failure appeared significantly more often (67.3%). Thus only 32.7% of the recipients needed no further dialysis. This difference is statistically significant.
D058186:Acute Kidney Injury / Q000517:prevention & control*; D000293:Adolescent; D000328:Adult; D002102:Cadaver; D006801:Humans; D007677:Kidney Function Tests; D016030:Kidney Transplantation; D009392:Nephrectomy; D011183:Postoperative Complications / Q000517:prevention & control*; D011292:Premedication; D012084:Renin-Angiotensin System / Q000187:drug effects; D012504:Saralasin / Q000627:therapeutic use*
D012504:Saralasin
Einfluss des Angiotensin II-Analogons-Saralasin bei Spendernierenentnahme auf die primäre Transplantatfunktion.